Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors (Q37473376)

20 August 2017

Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors (English)

1 reference

20 August 2017

1 reference

1 reference

Christopher Rowan

1

1 reference

20 August 2017

Allen D Brinker

2

1 reference

20 August 2017

Parivash Nourjah

3

1 reference

20 August 2017

Jennie Chang

4

1 reference

20 August 2017

Andrew Mosholder

5

1 reference

20 August 2017

Jeffrey S Barrett

6

1 reference

20 August 2017

Mark Avigan

7

1 reference

20 August 2017

1 April 2009

1 reference

Pharmacoepidemiology and Drug Safety

20 August 2017

1 reference

20 August 2017

18

1 reference

20 August 2017

4

1 reference

20 August 2017

301-309

1 reference

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug inter

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

HMG-CoA reductase inhibitors and myotoxicity

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

Cerivastatin and reports of fatal rhabdomyolysis

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

3 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890413

Risk factors for rhabdomyolysis with simvastatin and atorvastatin

3 December 2018

1 reference

12 December 2020

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions

1 reference

12 December 2020

Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations

1 reference

12 December 2020

Effect of itraconazole on the pharmacokinetics of atorvastatin

1 reference

12 December 2020

Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses

1 reference

12 December 2020

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects

1 reference

12 December 2020

Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid

1 reference

12 December 2020

Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat

1 reference

12 December 2020

Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans

1 reference

12 December 2020

Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug

1 reference

12 December 2020

Use of a spontaneous adverse drug events database for identification of unanticipated drug benefits

1 reference

12 December 2020

Identifiers

DOI

10.1002/PDS.1711

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

19206087

1 reference